AI Article Synopsis
- - Patients with inflammatory bowel disease in Hungary were studied after switching from original anti-TNF drugs to biosimilars, focusing on their feelings about efficacy and adverse events.
- - The study found that patients rated the subjective effectiveness of the IFX biosimilar lower than the original IFX, while the ADA biosimilar was rated higher than the original ADA.
- - A higher number of patients reported new adverse events after switching to the ADA biosimilar compared to the IFX biosimilar, indicating varying experiences with the treatments.
Article Abstract
Background: Few data are available on subjective disease control and perception of adverse events (AEs) during switching from original anti-TNF agents to biosimilars.
Research Design And Methods: Hungarian patients with inflammatory bowel disease were interviewed after a mandatory non-medical switch from an infliximab (IFX) originator to a biosimilar GP1111 or from an adalimumab (ADA) originator to a biosimilar GP2017. Drug choice was based on patient's and physician's decision. Subjective efficacy was measured using a 10-point scale, and AEs were assessed. Difference in efficacy before and after the switch was compared within and between the drugs.
Results: Seventy-three ADA and 106 IFX switching patients were interviewed. Subjective efficacy of IFX biosimilar was rated lower compared to IFX originator (8.72 ± 1.68 vs. 7.77 ± 2.34; = 0.001). The ADA biosimilar was rated higher than its originator (9.02 ± 1.61 vs. 8.42 ± 1.93; = 0.017). Patients receiving ADA biosimilar were more satisfied with the new treatment compared to IFX ( = 0.032). The incidence of new AEs was 85% in the ADA and 55% in the IFX group (1.79 vs. 0.93 AEs per patient, respectively, < 0.001).
Conclusion: Subjective efficacy of switching to a biosimilar was proven in case of ADA, while reduced efficacy was experienced with IFX biosimilar. Perception of AEs was high and varied between biosimilars.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14712598.2023.2211204 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aseptic abscess syndrome: a case report of a patient achieving remission with both infliximab originator and biosimilar administered at varied intervals.
Front Immunol
December 2024
Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Rheumatology Unit, Sapienza University of Rome, Rome, Italy.
Aseptic abscesses syndrome is a rare but increasingly recognized disease that falls within the spectrum of autoinflammatory disorders. Here, we describe the case of a patient who presented with abdominal pain and fever, along with multiple abdominal and extra-abdominal abscesses, in the absence of underlying hematologic, autoimmune, infectious, or neoplastic conditions. Initially, the patient responded to glucocorticoids, but experienced several flares upon discontinuation, leading to the initiation of treatment with a TNFα inhibitor.
View Article and Find Full Text PDFBudget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands.
J Med Econ
December 2025
Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
Objective: The objective of this study was to explore the financial consequences of adopting cenobamate as a treatment alternative in epilepsy patients with drug-resistant focal onset seizures (FOS) from a societal perspective in the Netherlands.
Methods: A previous budget impact model with a 5-year time horizon was adapted to the Dutch setting accounting for the eligible population, real-world market shares, treatment effectiveness and resource use in two scenarios: cenobamate with constant market share versus cenobamate with linearly increased market share up to 20%. Clinical inputs included treatment response, seizure reduction and adverse events.
Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease.
World J Gastroenterol
December 2024
Department of Gastroenterology, St. Paul's Hospital, Vancouver V6Z 1Y6, British Columbia, Canada.
Background: Over the last decade, the treatment options for inflammatory bowel disease (IBD) have significantly progressed with the emergence of new medications designed to target various immune pathways and mitigate inflammation. Adalimumab (ADA) is a tumor necrosis factor alpha antagonist and stands as an effective treatment for IBD. In April 2021, the province of British Columbia implemented a mandatory non-medical switch policy of the ADA originator Humira to ADA biosimilars.
View Article and Find Full Text PDFBackground: Use of online crowdfunding to mitigate health-related cost burden is common in the US, but its usage among candidates for metabolic and bariatric surgery (MBS) is unknown. We aimed to identify GoFundMe campaigns fundraising for MBS and characterize sources of financial strain. We also aimed to determine factors associated with successful crowdfunding.
View Article and Find Full Text PDFSwitching from rituximab originator to GP2013 or CT-P10 biosimilars in autoimmune rheumatic diseases: drug retention rate and safety data from a multicentric retrospective cohort.
Ther Adv Musculoskelet Dis
November 2024
Department of Medicine, Surgery and Neurosciences, Rheumatology Unit of Azienda Ospedaliero-Universitaria Senese, University of Siena, Siena, Italy.
Article Synopsis
- The study evaluates the safety and effectiveness of switching from the original rituximab (RTX-O) to its biosimilars (RTX-B) in patients with autoimmune rheumatic diseases (ARDs), with a focus on long-term drug retention and safety.
- It included 181 patients who switched to either GP2013 or CT-P10, finding that the drug retention rates were high over 36 months, particularly for GP2013.
- The transition to CT-P10 showed a higher risk of discontinuation, but overall, the switch to RTX-B was deemed safe with a low incidence of adverse events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!